eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Randomized study of vincristine, dactinomycin and cyclophosphamide (VAC) versus VAC alternating with vincristine and irinotecan (VI) for patients with intermediate-risk rhabdomyosarcoma (RMS)

eagle-i ID

http://hawaii.eagle-i.net/i/00000130-d356-b34b-9953-50a980000000

Resource Type

  1. Clinical trial

Properties

  1. ClinicalTrials.gov url
    http://www.clinicaltrials.gov/ct2/show/NCT00354835?term=A+Phase+III+Randomized+Study+of+Vincristine%2C+Dactinomycin+and+Cyclophosphamide+%28VAC%29+versus+VAC+Alternating+with+Vincristine+and+Irinotecan+%28VI%29+for+patients+with+Intermediate-Risk+Rhabdomyosarcoma+%28RMS%29.&rank=1
  2. Intervention
    Tumor resection
  3. Intervention
    Radiation therapy
  4. Resource Description
    Rhabdomyosarcoma is the most common soft tissue sarcoma in children and adolescents, accounting for nearly 250 cases of childhood cancer in the United States each year. Despite the use of multiple drug therapies, only 65% of intermediate-risk patients are expected to be cured. The overall goal of this study is to see if we can increase this cure rate without causing more serious side effects of treatment. Researchers want to know if they can improve the cure rate for Intermediate-Risk Rhabdomyosarcoma by treating with surgery to remove as much tumor as possible, radiation therapy and chemotherapy. Participants in the study will receive one of two different treatment plans. Another goal of this study is to compare a new schedule of giving radiation therapy at week 4 compared to the standard schedule of starting at week 13. Other studies of radiation timing for other cancers have shown improved outcomes when radiation was given earlier in the treatment plan. A slightly lower dose of cyclophosphamide will also be given to compare side effects of the higher standard dose.
  5. Contact
    Berenberg, Jeffrey
  6. PI
    Wilkinson, Robert, M.D.
  7. Topic
    rhabdomyosarcoma
  8. Study Population
    Patients younger than 50 years old who are newly diagnosed with intermediate-risk rhabdomyosarcoma, either embryonal or alveolar.
  9. Funded by
    Children's Oncology Group
  10. Phase
    Phase 3 clinical trial
  11. Performed by
    Clinical Protocol & Data Management Shared Resource
 
RDFRDF
 
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016